Results 141 to 150 of about 9,852 (179)

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. [PDF]

Clin Transl Med
Martino EA, Caserta S, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M.   +12 more
europepmc   +1 more source

Targeting CDK11 in Rhabdoid Tumor of the Kidney. [PDF]

Cancers (Basel)
Murakami Y, Lam K, Fukui S, Helmke E, Iczkowski KA, Li Y, Satake N.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Uveal Melanomas with SF3B1 Mutations

Ophthalmology, 2016
Dion Paridaens, Jolanda Vaarwater, Annelies De Klein   +2 more
exaly   +2 more sources

Significance of SF3B1 Mutations in Myeloid Neoplasms

Clinics in Laboratory Medicine, 2023
Myelodysplastic neoplasm with low blasts and SF3B1 mutation (MDS-LB-SF3B1) has undergone significant classification changes in the past year with the publication of the 5th edition of the World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues and the International Consensus Classification.
David C, Gajzer, Cecilia C S, Yeung
openaire   +2 more sources

Role Of Sf3b1 On Hematopoiesis

Blood, 2013
Abstract Frequent pathway mutation involving multiple components of the RNA splicing machinery is a cardinal feature of myeloid neoplasms showing myeloid dysplasia, in which the major mutational targets include U2AF35, ZRSR2, SRSF2 and SF3B1.
Manabu Matsunawa, Ryo Yamamoto, Masashi Sanada, Aiko Sato, Yusuke Shiozawa, Kenichi Yoshida, Yasunobu Nagata, Ayana Kon, Tetsuichi Yoshizato, Makoto Otsu, Kyoichi Isono, Haruhiko Koseki, Hiromitsu Nakauchi, Seishi Ogawa   +13 more
openaire   +1 more source

SF3B1in Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2012
To the Editor: Wang et al. (Dec. 29 issue)1 report that SF3B1 mutation is associated with a shorter time to initiation of treatment in patients with chronic lymphocytic leukemia. However, this result should be interpreted with caution. In the discovery cohort of 91 patients, 29 were classified as having stage 0 disease, 43 as having stage I, and 19 as ...
Jinichi, Mori, Yukie, Takahashi, Tetsuya, Tanimoto   +2 more
openaire   +2 more sources

Impact of SF3B1 mutation on outcomes in myelofibrosis.

Journal of Clinical Oncology, 2022
e19080 Background: Splicing factor 3B subunit 1 ( SF3B1) mutations have been shown to confer a unique phenotype in MDS and MDS/MPN overlap syndromes, with ring sideroblasts, thrombocytosis and favorable prognosis. In myelofibrosis (MF) the frequency of SF3B1 mutation is <10% and may play a less important role in disease outcomes (Lasho et.
Prithviraj Bose, Jayastu Senapati, Lucia Masarova, Naveen Pemmaraju, Guillermo Montalban Bravo, Sherry Pierce, Lingsha Zhou, Guillermo Garcia-Manero, Hagop M. Kantarjian, Srdan Verstovsek   +9 more
openaire   +1 more source

Chronic Lymphocytic Leukemia withSF3B1Mutation

New England Journal of Medicine, 2012
The authors found that chronic lymphocytic leukemia in patients with mutations in the SF3B1 RNA splicing gene has a more aggressive natural history than that in patients without such mutations.
Victor, Quesada, Andrew J, Ramsay, Carlos, Lopez-Otin   +2 more
openaire   +2 more sources

Abstract 4615: Influence of SF3B1 gene mutation is different from that of Sf3B1 inhibitor in colorectal cancer

Cancer Research, 2014
Abstract Purpose: We have reported that SF3B1 gene mutations are rare in colorectal cancer patients and SF3B1 gene mutations in codon 1074 are responsible for resistance to SF3B1 inhibitor (FR901464, FR) at the AACR annual meeting 2013. SF3B1 gene mutations in hematological malignancies are considered to be related to tumor progression ...
Tomoki Yamano, Shuji Kubo, Nagahide Matsubara, Aya Yano, Naohiro Tomita   +4 more
openaire   +1 more source

The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia

IUBMB Life, 2022
AbstractThe discovery of new genes/pathways improves our knowledge of cancer pathogenesis and presents novel potential therapeutic options. For instance, splicing factor 3b subunit 1 (SF3B1) and NOTCH1 genetic alterations have been identified at a high frequency in hematological malignancies, such as leukemia, and may be related to the prognosis of ...
Shiva Abolhasani, Seyyed Sina Hejazian, Vahid Karpisheh, Atefeh Khodakarami, Hamed Mohammadi, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat‐Farsangi, Farhad Jadidi‐Niaragh   +7 more
openaire   +2 more sources